No abstract available.
Granuloma, Foreign-Body* ; Leuprolide*

No abstract available.
Leuprolide* ; Pityriasis Rosea* ; Pityriasis*

No abstract available.
Endometriosis ; Female ; Leuprolide* ; Pityriasis Rosea*

OBJECTIVE: The aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM) or gonadotropin-releasing hormone (GnRH) agonist on uterine fibroid shrinkage among Korean women. METHODS: This retrospective study involved 101 women with symptomatic uterine fibroids who received ulipristal acetate (SPRM, n=51) and leuprolide acetate (GnRH agonist, n=50) for 3 months between November 2013 and February 2015. The fibroid volume was measured both before and after treatment using ultrasonography, computed tomography, and magnetic resonance imaging. The outcomes were compared between the SPRM and GnRH agonist groups. RESULTS: The median rate of fibroid volume reduction after SPRM treatment was 12.4% (IQR −14.5% to 40.5%) which was significantly lower than the reduction rate observed after GnRH agonist treatment (median 34.9%, IQR 14.7% to 48.6%, P=0.004). 19 of 51 (37.3%) patients with SPRM treatment did not show any response of volume shrinkage, while 7 of 50 (14.0%) women with GnRH agonist showed no response (P=0.007). CONCLUSION: Short-term SPRM treatment yields lower volume reduction than GnRH agonist treatment in Korean women with symptomatic fibroids. Further large-scale randomized trials are needed to confirm our findings.
Female ; Gonadotropin-Releasing Hormone* ; Humans ; Leiomyoma* ; Leuprolide ; Magnetic Resonance Imaging ; Progesterone* ; Receptors, Progesterone* ; Retrospective Studies ; Ultrasonography

OBJECTIVES: To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS: Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment cycles. RESULTS: At cycle 12 of GnRH-a plus raloxifene treatment, lumbar spine, trochanter femoral neck, and Ward's BMD differed from before the treatment. A year after treatment, the lumbar spine and trochanter decreased slightly, but were not significantly different. CONCLUSIONS: Our study shows that the administration of GnRH-a plus raloxifene in pre-menopausal women with severe endometriosis, is an effective long-term treatment to prevent bone loss.
Bone Density* ; Endometriosis* ; Female ; Femur ; Femur Neck ; Gonadotropin-Releasing Hormone* ; Humans ; Leuprolide ; Raloxifene Hydrochloride* ; Spine

This study investigated the effect of leuprolide acetate treatment on sex offenders' sexual fantasies and behaviors, as well as on their criminogenic psychological character and the risk of second conviction. The study participants consisted of 22 sex offenders who were confined to the National Institute of Forensic Psychiatry. Among them, 9 patients were given off-label leuprolide acetate for three months to inhibit sexual impulses, whereas the others were not given any medication. All sex offenders underwent two psychological evaluations; the first evaluation was conducted before starting medication, and the second was conducted after medication. Wilson's Sex Fantasy Questionnaire (WSFQ), the Rape Myth Acceptance Scale (RMAS), and the Endorsement of Violence Scale (EVS) were used for evaluation. Leuprolide acetate-treated sex offenders showed a statistically significant decline in the total WSFQ score (p < 0.05). However, the RMAS and EVS scores did not differ after leuprolide acetate treatment, indicating that cognitive distortions like rape myth acceptance and endorsement of violence were unchanged after leuprolide medication. Leuprolide acetate may reduce deviant sexual impulses and fantasies, as suggested by previous research form Korea and other countries. However, it probably cannot alter cognitive distortion. On the basis of these findings, we recommend a combination of leuprolide medication and other therapies, like cognitive behavioral therapy, for the treatment of paraphilic sex offenders.
Cognitive Therapy ; Criminals ; Fantasy ; Forensic Psychiatry ; Humans ; Korea ; Leuprolide ; Paraphilic Disorders ; Rape ; Violence ; Surveys and Questionnaires

PURPOSE: We evaluated the efficacy, safety and psychological aspect of monthly administrations of the gonadotropin-releasing hormone agonists (GnRHa), leuprolide acetate depot (Luphere depot 3.75 mg), in patients with precocious puberty. METHODS: A total of 54 girls with central precocious puberty were administered with leuprolide acetate (Luphere depot 3.75 mg) every four weeks over 24 weeks. We evaluated the percentage of children exhibiting a suppressed luteinizing hormone (LH) response to GnRH (LH peak< or =3 IU/L), peak LH/follicle stimulating hormone (FSH) ratio of GnRH stimulation test less than 1, change in bone age/chronologic age ratio, change in the Tanner stage and change in eating habit and psychological aspect. RESULTS: (1) The percentage of children exhibiting a suppressed LH response to GnRH, defined as an LH peak< or =3 IU/L at 24 weeks was 96.3 % (52/54). (2) The percentage of children exhibiting peak LH/FSH ratio<1 at 24 weeks of the study was 94.4 % (51/54). (3) The ratio of bone age and chronological age significantly declined from 1.27+/-0.07 to 1.24+/-0.01 after the 6 months of the study. (4) The mean Tanner stage manifested a significant change 2.3+/-0.48 at baseline, down to 1.70+/-0.61 at 24 weeks. (5) Based on the questionnaires, the score for eating habits showed a significant change from the baseline 34.0+/-6.8 to 31.3+/-6.8. (6) The psychological assessment did not exhibit a significant difference except with scores for sociability, problem behavior total score and other problems. CONCLUSION: The leuprolide 3.75 mg (Luphere depot) is useful and safety for treating children with central precocious puberty.
Child ; Eating ; Female* ; Gonadotropin-Releasing Hormone ; Humans ; Leuprolide* ; Luteinizing Hormone ; Puberty, Precocious* ; Treatment Outcome ; Surveys and Questionnaires

Recently LHRH analog has been interested in the endocrine management of metastatic prostatic. cancer. But the effect of LHRH analog therapy on the prostate has not been previously documented definitely. And the initial flare phenomenon may be developed after initiation of LHRH analog therapy, but the definite method to block this phenomenon has not been introduced. To assess the effect of LHRH analog administration on the prostate, The author observed the weight and histopathologic changes of rat prostate during the administration of a potent LHRH analog (leuprolide acetate) for 6 weeks. And the author intended to present a possible method to block the initial flare phenomenon by observation of the weight and histopathologic changes of rat prostate after local testicular irradiation with a minimal dose(500 rad) producing Leydig cell dysfunction. The following results were obtained: 1. The prostate weight in control group was progressively increased during experimental periods At 0 day, 3 weeks and 6 weeks of experimental period, the prostate weights were 0.44gm, 0 58gm and 0.64gm respectively. 2. The prostate weight in leuprolide treated group was significantly decreased at 3 weeks(0.40+/-0.02gm) and 6 weeks (0.30+/-0.04gm) of administration in contrast to the age-matched control group (p<0.05). 3. The prostate weight in testicular irradiation group was significantly decreased at 3 weeks(0.44+/-0.04gm) and 6 weeks(0.42+/-0.02gm) after irradiation in contrast to the age-matched control group(p<0.05). But its change was less prominent than leuprolide treated group. 4. The pathologic change of prostate after leuprolide administration was the vacuolization of acinar cells. The vacuolization was noticed at 2 weeks of administration and pro gressively increased to the 6 weeks. 5. The pathologic change of prostate after testicular irradiation was the progressively increased vacuolization of acinar cells during experimental periods, but its change was less significant than leuprolide treated group. These results suggest that LHRH analog develops the progressive vacuolization of acinar cells, causing the regression of acinar cells and prostatic atrophy as well as the possible inhibition of normal prostatic growth and that local testicular irradiation prior to LHRH analog therapy may be a possible method to block the initial flare phenomenon.
Acinar Cells ; Animals ; Atrophy ; Gonadotropin-Releasing Hormone* ; Leuprolide ; Prostate* ; Rats* ; Testis ; Weights and Measures

OBJECTIVE: To evaluate the clinical efficacy and safety of Lorelin(R), a depot form of leuprorelin acetate made in Korea, in the treatment of endometriosis. MATERIALS AND METHODS: Twenty patients with surgically proven endometriosis were recruited and followed during about 21 weeks of treatment. Lorelin(R) 3.75 mg was injected every 4 weeks after the first injection following initial operation and a total of six doses were injected to a patient. Symptom severity score, chemical battery, lipid battery, and serum levels of follicule stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and CA-l25 were assayed before Lorelin(R) treatment, after 3 doses, and after 6 doses. Statistical analysis was performed utilizing repeated analysis of variance (ANOVA) and results with P-value less than 0.05 were considered significant. RESULTS: The age range at initial operation was 25 to 48 and the mean age was 36.5+/-6.1 (mean+/-SD) years. Symptom severity score and serum levels of LH, FSH, E2, and CA-125 were significantly lower after 3 and 6 doses of Lorelin(R) than before treatment. Transient elevation of liver enzyme was observed in 2 patients after 3 doses of Lorelin(R). Side effects were mainly due to treatment-induced hypoestrogenism and the most frequent symptom was hot flush (55%), vaginal dryness (30%), transient nausea sense (25%), and arthralgia (25%). All patients were able to tolerate these symptoms and no one discontinued Lorelin(R) therapy. CONCLUSION: This study suggests that Lorelin(R) could be an effective and safe regimen in the treatment of endometriosis.
Arthralgia ; Endometriosis* ; Estradiol ; Female ; Humans ; Korea ; Leuprolide* ; Liver ; Luteinizing Hormone ; Nausea

PURPOSE: The objective of this study was to evaluate the effect of gonadotropin releasing hormone analog (GnRHa) treatment on bone mineral density (BMD) in girls with central precocious puberty (CPP). Further we investigated the differences in the effect on BMD by using the GnRHa leuprolide-acetate and triptorelin. METHODS: Sixty-one females with CPP were enrolled in the study, the lumbar spine BMD was measured by dual energy x-ray absorptiometry before treatment, after one year (n = 61) and after two years (n = 24) of treatment. Lumbar spine BMD standard deviation scores (SDS) were compared according to chronological age (CA) and bone age (BA) for the whole group, as well as for the group A, treated with leuprolide-acetate (n = 40), and the group B, treated with triptorelin (n = 21). RESULTS: All subjects showed significant increment in BMD during treatment (P < 0.05). Lumbar spine BMD SDS for CA and BA showed no significant changes before and during treatment. Group A and group B, within each group, showed no significant changes in lumbar spine BMD SDS for CA and BA during treatment. CONCLUSION: Our study suggests that lumbar spine BMD was not impaired in girls treated with GnRHa for CPP and both leuprolide-acetate and triptorelin showed comparable effects on lumbar spine BMD during treatment.
Absorptiometry, Photon ; Bone Density ; Female ; Gonadotropin-Releasing Hormone ; Humans ; Leuprolide ; Piperazines ; Puberty, Precocious ; Spine ; Triptorelin Pamoate